Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AZ's Gout Drug PASS-ed In Europe

This article was originally published in Scrip

Executive Summary

The European Commission has given the green light for AstraZeneca to begin marketing Zurampic (lesinurad, 200mg) in combination with a xanthine oxidase inhibitor (allopurinol or febuxostat) for the adjunctive treatment of high uric acid levels in the blood associated with gout.